These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22730093)

  • 41. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive value of Dmax and %ΔSUVmax of
    Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
    BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Kim J; Song YS; Lee JS; Lee WW; Kim SE
    Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Med Oncol; 2017 Feb; 34(2):29. PubMed ID: 28083854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
    Martelli M; Ceriani L; Zucca E; Zinzani PL; Ferreri AJ; Vitolo U; Stelitano C; Brusamolino E; Cabras MG; Rigacci L; Balzarotti M; Salvi F; Montoto S; Lopez-Guillermo A; Finolezzi E; Pileri SA; Davies A; Cavalli F; Giovanella L; Johnson PW
    J Clin Oncol; 2014 Jun; 32(17):1769-75. PubMed ID: 24799481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.
    Huang H; Xiao F; Han X; Zhong L; Zhong H; Xu L; Zhu J; Ni B; Liu J; Fang Y; Zhang M; Shen L; Wang T; Liu J; Shi Y; Chen Y; Zheng L; Liu Q; Chen F; Wang J
    Nucl Med Commun; 2016 Jul; 37(7):689-98. PubMed ID: 27244584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
    Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
    J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
    Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
    Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.
    Ishii Y; Tomita N; Tateishi U; Ishiyama Y; Yamamoto E; Hattori Y; Hagihara M; Yamazaki E; Ishigatsubo Y
    Med Oncol; 2014 Mar; 31(3):880. PubMed ID: 24504845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
    Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
    Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary bone lymphoma involving bilateral tibia.
    Giardino AA; Shinagare AB; Shinagare SA; Dewar R; Weckstein D; Mauch P; Ramaiya NH; Freedman AS
    Am J Hematol; 2012 Sep; 87(9):924-5. PubMed ID: 22641233
    [No Abstract]   [Full Text] [Related]  

  • 57. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
    Chihara D; Oki Y; Ine S; Kato H; Onoda H; Taji H; Kagami Y; Yamamoto K; Morishima Y
    Eur J Haematol; 2010 Jun; 84(6):493-8. PubMed ID: 20148943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
    Casasnovas RO; Meignan M; Berriolo-Riedinger A; Bardet S; Julian A; Thieblemont C; Vera P; Bologna S; Brière J; Jais JP; Haioun C; Coiffier B; Morschhauser F;
    Blood; 2011 Jul; 118(1):37-43. PubMed ID: 21518924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.